ZA202100721B - Anti-mesothelin antibodies - Google Patents
Anti-mesothelin antibodiesInfo
- Publication number
- ZA202100721B ZA202100721B ZA2021/00721A ZA202100721A ZA202100721B ZA 202100721 B ZA202100721 B ZA 202100721B ZA 2021/00721 A ZA2021/00721 A ZA 2021/00721A ZA 202100721 A ZA202100721 A ZA 202100721A ZA 202100721 B ZA202100721 B ZA 202100721B
- Authority
- ZA
- South Africa
- Prior art keywords
- mesothelin antibodies
- antibody molecules
- mesothelin
- msln
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1811415.7A GB201811415D0 (en) | 2018-07-12 | 2018-07-12 | Anti-Mesothelin Anti bodies |
| PCT/EP2019/068800 WO2020011970A1 (en) | 2018-07-12 | 2019-07-12 | Anti-mesothelin antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202100721B true ZA202100721B (en) | 2026-03-25 |
Family
ID=63273221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2021/00721A ZA202100721B (en) | 2018-07-12 | 2021-02-02 | Anti-mesothelin antibodies |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US12325742B2 (https=) |
| EP (1) | EP3820908A1 (https=) |
| JP (2) | JP7431211B2 (https=) |
| KR (1) | KR20210030957A (https=) |
| CN (1) | CN112703205B (https=) |
| AU (1) | AU2019303030B2 (https=) |
| BR (1) | BR112021000399A2 (https=) |
| CA (1) | CA3105995A1 (https=) |
| GB (1) | GB201811415D0 (https=) |
| IL (1) | IL280003A (https=) |
| MX (1) | MX2021000392A (https=) |
| SG (1) | SG11202013164RA (https=) |
| TW (1) | TWI840386B (https=) |
| WO (1) | WO2020011970A1 (https=) |
| ZA (1) | ZA202100721B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190022632A (ko) | 2016-06-20 | 2019-03-06 | 에프-스타 베타 리미티드 | Lag-3 결합 구성원 |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| JP7332627B2 (ja) | 2018-04-25 | 2023-08-23 | プロメテウス バイオサイエンシーズ，インク． | 最適化された抗ｔｌ１ａ抗体 |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| PL3820569T3 (pl) | 2018-07-12 | 2025-07-14 | Invox Pharma Limited | Cząsteczki przeciwciał, które wiążą PD-L1 oraz CD137 |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| BR112021000282A2 (pt) | 2018-07-12 | 2021-04-06 | F-Star Beta Limited | Moléculas de anticorpo que se ligam a cd137 e ox40 |
| KR20220103721A (ko) | 2019-10-24 | 2022-07-22 | 프로메테우스 바이오사이언시즈, 인크. | Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도 |
| EP4132969A4 (en) * | 2020-04-07 | 2024-05-01 | Fred Hutchinson Cancer Center | ANTI-MESOTHELIN ANTIGEN-BINDING MOLECULES AND USES THEREOF |
| CN111560072B (zh) * | 2020-07-16 | 2020-12-11 | 上海恒润达生生物科技有限公司 | 抗人msln抗体以及靶向msln的免疫效应细胞 |
| WO2022262859A1 (zh) * | 2021-06-18 | 2022-12-22 | 江苏先声药业有限公司 | 抗人msln人源化抗体及其应用 |
| TW202321296A (zh) | 2021-10-06 | 2023-06-01 | 美商鏈接免疫療法公司 | 抗間皮素抗原結合分子及其用途 |
| CN115991782A (zh) * | 2021-10-18 | 2023-04-21 | 普米斯生物技术(珠海)有限公司 | 抗间皮素纳米抗体及其用途 |
| WO2023115528A1 (en) * | 2021-12-24 | 2023-06-29 | Zhejiang Shimai Pharmaceutical Co., Ltd. | Antibodies against mesothelin and uses thereof |
| KR20250052374A (ko) * | 2022-07-11 | 2025-04-18 | 노나 바이오사이언시즈 (수조우) 컴퍼니 리미티드 | 항-메소텔린 항체 |
| WO2025116545A1 (ko) * | 2023-11-27 | 2025-06-05 | 건국대학교 글로컬산학협력단 | 신규한 항-메소텔린 항체 및 이의 용도 |
| KR20250160321A (ko) * | 2024-05-03 | 2025-11-12 | 서울대학교산학협력단 | 항-메소텔린 항체 및 이의 용도 |
| WO2026039642A1 (en) * | 2024-08-16 | 2026-02-19 | Ardeagen Corporation | Anti-mesothelin antibody conjugates and methods of use thereof |
Family Cites Families (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2245404C3 (de) | 1972-09-15 | 1978-08-31 | Robert Bosch Gmbh, 7000 Stuttgart | Massewiderstand, insbesondere für Zündkerzen, sowie Verfahren zur Herstellung desselben |
| JPS531908B2 (https=) | 1973-11-12 | 1978-01-23 | ||
| JPS5746634B2 (https=) | 1974-05-10 | 1982-10-04 | ||
| JPS5146628A (ja) | 1974-10-17 | 1976-04-21 | Nippon Denso Co | Teikoirisupaakupuragu |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| ATE317437T1 (de) | 1997-12-01 | 2006-02-15 | Us Gov Health & Human Serv | Antikörper, sowie fv moleküle, und immunkonjugate mit hoher bindungsaffinität für mesothelin und methoden für deren verwendung |
| DE19818214A1 (de) | 1998-04-24 | 1999-10-28 | Bosch Gmbh Robert | Zündkerze für eine Brennkraftmaschine |
| DK1180123T3 (da) | 1999-05-27 | 2008-10-13 | Us Gov Health & Human Serv | Immunkonjugater, der har höj bindingsaffinitet |
| CN101289511A (zh) | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
| JP4578025B2 (ja) | 2001-07-06 | 2010-11-10 | 日本特殊陶業株式会社 | スパークプラグ |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| CN103555733A (zh) | 2005-01-05 | 2014-02-05 | F-星生物技术研究与开发有限公司 | 分子中互补决定区以外的区域中工程改造了的具有结合特性的合成免疫球蛋白结构域 |
| WO2006088447A1 (en) | 2005-02-15 | 2006-08-24 | Gtc Biotherapeutics, Inc. | An anti-cd137 antibody as an agent in the treatement of cancer and glycosylation variants thereof |
| CA2600505C (en) | 2005-03-10 | 2016-05-03 | Morphotek, Inc. | Anti-mesothelin antibodies |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| AU2006301492B2 (en) | 2005-10-11 | 2011-06-09 | Amgen Research (Munich) Gmbh | Compositions comprising cross-species-specific antibodies and uses thereof |
| AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
| GB0624500D0 (en) | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| EP3241842B1 (en) | 2007-06-26 | 2024-01-31 | F-star Therapeutics Limited | Display of binding agents |
| EP3103814A1 (en) | 2007-11-26 | 2016-12-14 | Bayer Intellectual Property GmbH | Anti-mesothelin antibodies and uses therefor |
| DK2851374T3 (en) | 2007-12-14 | 2017-06-19 | Bristol Myers Squibb Co | Binding molecules to the human OX40 receptor |
| EP2365003A1 (en) | 2008-04-11 | 2011-09-14 | Emergent Product Development Seattle, LLC | CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| RU2526156C2 (ru) | 2008-11-13 | 2014-08-20 | ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи | Cd37-иммунотерапевтическая комбинированная терапия и ее применения |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| US8460660B2 (en) | 2009-03-24 | 2013-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Anti-mesothelin antibodies |
| AR076284A1 (es) | 2009-04-29 | 2011-06-01 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| EP3009455A1 (en) | 2009-09-16 | 2016-04-20 | Immunomedics Inc. | Class i anti-cea antibodies and uses thereof |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| EP2407487A1 (en) | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispecific modular antibody |
| PT2614082T (pt) | 2010-09-09 | 2018-12-03 | Pfizer | Moléculas de ligação a 4-1bb |
| PE20141114A1 (es) | 2010-12-20 | 2014-09-15 | Genentech Inc | Anticuerpos anti-mesotelina e inmunoconjugados |
| SG10201602394QA (en) | 2011-03-29 | 2016-05-30 | Roche Glycart Ag | Antibody FC Variants |
| EP2546268A1 (en) | 2011-07-13 | 2013-01-16 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Internalising immunoglobulin |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| HK1204557A1 (en) | 2012-05-31 | 2015-11-27 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-l1 |
| US20140004121A1 (en) | 2012-06-27 | 2014-01-02 | Amgen Inc. | Anti-mesothelin binding proteins |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| JP5276742B1 (ja) | 2012-08-09 | 2013-08-28 | 日本特殊陶業株式会社 | 点火プラグ |
| CN104955845B (zh) | 2012-09-27 | 2018-11-16 | 美国政府(由卫生和人类服务部的部长所代表) | 间皮素抗体和引起有效的抗肿瘤活性的方法 |
| CN104968364A (zh) | 2012-12-03 | 2015-10-07 | 百时美施贵宝公司 | 强化免疫调变性Fc融合蛋白的抗癌活性 |
| AU2014236769B2 (en) | 2013-03-15 | 2018-09-27 | Amgen Inc. | Heterodimeric bispecific antibodies |
| EA037554B1 (ru) | 2013-03-15 | 2021-04-13 | Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Анти-lag-3 связывающие белки |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| GB201317622D0 (en) | 2013-10-04 | 2013-11-20 | Star Biotechnology Ltd F | Cancer biomarkers and uses thereof |
| EP3686219A1 (en) | 2014-02-04 | 2020-07-29 | Pfizer Inc | Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer |
| US20150259420A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| US20150307620A1 (en) | 2014-04-16 | 2015-10-29 | University Of Connecticut | Linked immunotherapeutic agonists that costimulate multiple pathways |
| WO2015198312A1 (en) | 2014-06-24 | 2015-12-30 | Ccam Therapeutics Ltd. | Compositions comprising antibodies to ceacam-1 and lag-3 for cancer therapy |
| JP5902757B2 (ja) | 2014-06-24 | 2016-04-13 | 日本特殊陶業株式会社 | スパークプラグ |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| CN106716752B (zh) | 2014-08-10 | 2019-01-04 | 费德罗-莫格尔点火公司 | 具有改进的密封的火花塞 |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| ES2771926T3 (es) | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
| TW201619200A (zh) | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗－ｏｘ４０抗體及其用途 |
| CA2874083C (en) | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| EP3623386B1 (en) | 2015-01-08 | 2022-04-13 | BioNTech SE | Agonistic tnf receptor binding agents |
| GB201500319D0 (en) | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| TW201632559A (zh) | 2015-02-22 | 2016-09-16 | 索倫多醫療公司 | 結合ｃｄ１３７之抗體治療劑 |
| TW201642897A (zh) | 2015-04-08 | 2016-12-16 | Ｆ 星生物科技有限公司 | Ｈｅｒ２結合劑治療 |
| KR20170138574A (ko) | 2015-05-04 | 2017-12-15 | 피어이스 파마슈티컬즈 게엠베하 | 항암 융합 폴리펩타이드 |
| JP2018520650A (ja) | 2015-05-21 | 2018-08-02 | アリゲーター・バイオサイエンス・アーベー | 新規のポリペプチド |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| JP6025921B1 (ja) | 2015-06-22 | 2016-11-16 | 日本特殊陶業株式会社 | スパークプラグ |
| KR20180029238A (ko) | 2015-07-15 | 2018-03-20 | 피어이스 파마슈티컬즈 게엠베하 | Lag-3에 특이적인 신규 단백질 |
| CA2993177A1 (en) | 2015-07-22 | 2017-01-26 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind lag3 |
| WO2017019846A1 (en) | 2015-07-30 | 2017-02-02 | Macrogenics, Inc. | Pd-1-binding molecules and methods use thereof |
| WO2017025498A1 (en) | 2015-08-07 | 2017-02-16 | Pieris Pharmaceuticals Gmbh | Novel fusion polypeptide specific for lag-3 and pd-1 |
| HRP20201022T1 (hr) | 2015-09-22 | 2020-10-16 | Dingfu Biotarget Co., Ltd | Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba |
| KR101782487B1 (ko) | 2015-09-24 | 2017-09-27 | 재단법인 목암생명과학연구소 | 신규 항-메소텔린 항체 및 이를 포함하는 조성물 |
| PE20240096A1 (es) | 2015-10-02 | 2024-01-18 | Hoffmann La Roche | Anticuerpos biespecificos especificos para un receptor de tnf coestimulador |
| TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| GB201519481D0 (en) | 2015-11-04 | 2015-12-16 | Cancer Rec Tech Ltd | Immunomodulatory antibodies |
| MA43260A (fr) | 2015-11-18 | 2018-09-26 | Merck Sharp & Dohme | Liants pd1 et/ou lag3 |
| WO2017087901A2 (en) | 2015-11-19 | 2017-05-26 | Sutro Biopharma, Inc. | Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies |
| KR20180096789A (ko) | 2016-01-11 | 2018-08-29 | 인히브릭스, 인크. | 다가 및 다중특이적 41bb-결합 융합 단백질 |
| KR102211384B1 (ko) | 2016-03-18 | 2021-02-03 | 다이니폰 인사츠 가부시키가이샤 | 중간 전사 매체, 중간 전사 매체와 열전사 시트의 조합 및 인화물의 형성 방법 |
| AU2017252233A1 (en) | 2016-04-22 | 2018-11-15 | Alligator Bioscience Ab | Novel bispecific polypeptides against CD137 |
| AR108377A1 (es) | 2016-05-06 | 2018-08-15 | Medimmune Llc | Proteínas de unión biespecíficas y sus usos |
| BR112018074453A2 (pt) | 2016-05-27 | 2019-03-19 | Abbvie Biotherapeutics Inc. | proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral |
| US20190106494A1 (en) | 2016-06-13 | 2019-04-11 | Askgene Pharma Inc. | PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis |
| KR102664891B1 (ko) | 2016-06-20 | 2024-05-13 | 에프-스타 테라퓨틱스 리미티드 | Pd-l1 및 lag-3에 결합하는 결합 분자 |
| CN107523546A (zh) * | 2016-06-20 | 2017-12-29 | 上海细胞治疗研究院 | 一种高效稳定表达抗体的nk细胞及其用途 |
| KR20190022632A (ko) | 2016-06-20 | 2019-03-06 | 에프-스타 베타 리미티드 | Lag-3 결합 구성원 |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| EP3487883B1 (en) | 2016-07-20 | 2023-01-04 | Stcube, Inc. | Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1 |
| BR112019005895A2 (pt) | 2016-09-23 | 2019-06-11 | Merus N.V. | moléculas de ligação que modulam uma atividade biológica expressa por uma célula |
| GB201616699D0 (en) | 2016-09-30 | 2016-11-16 | Mab Designs Ltd | Antibodies |
| GB201619648D0 (en) | 2016-11-21 | 2017-01-04 | Alligator Bioscience Ab | Novel antibodies and uses thereof |
| WO2018115859A1 (en) | 2016-12-20 | 2018-06-28 | Kymab Limited | Multispecific antibody with combination therapy for immuno-oncology |
| GB201700345D0 (en) | 2017-01-09 | 2017-02-22 | F-Star Beta Ltd | Conditional agonists of immune responses |
| JP7220161B2 (ja) | 2017-05-26 | 2023-02-09 | ノビミューン エスアー | 抗ＣＤ４７ｘ抗メソテリン抗体およびそれを使用する方法 |
| US20210340250A1 (en) | 2017-05-30 | 2021-11-04 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
| SG11202000198QA (en) | 2017-08-04 | 2020-02-27 | Genmab As | Binding agents binding to pd-l1 and cd137 and use thereof |
| EP3470426A1 (en) | 2017-10-10 | 2019-04-17 | Numab Therapeutics AG | Multispecific antibody |
| WO2019121906A1 (en) | 2017-12-19 | 2019-06-27 | F-Star Beta Limited | Specific pd-l1 binding sequences inserted in a ch3 domain |
| EP3728314A1 (en) | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| BR112021000282A2 (pt) | 2018-07-12 | 2021-04-06 | F-Star Beta Limited | Moléculas de anticorpo que se ligam a cd137 e ox40 |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| PL3820569T3 (pl) | 2018-07-12 | 2025-07-14 | Invox Pharma Limited | Cząsteczki przeciwciał, które wiążą PD-L1 oraz CD137 |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| KR20220008316A (ko) | 2019-05-14 | 2022-01-20 | 에프-스타 테라퓨틱스 리미티드 | Lag-3/pd-l1 이중특이적 항체의 투여를 위한 투여 요법 |
-
2018
- 2018-07-12 GB GBGB1811415.7A patent/GB201811415D0/en not_active Ceased
-
2019
- 2019-07-12 CA CA3105995A patent/CA3105995A1/en active Pending
- 2019-07-12 WO PCT/EP2019/068800 patent/WO2020011970A1/en not_active Ceased
- 2019-07-12 TW TW108124779A patent/TWI840386B/zh active
- 2019-07-12 SG SG11202013164RA patent/SG11202013164RA/en unknown
- 2019-07-12 BR BR112021000399-1A patent/BR112021000399A2/pt unknown
- 2019-07-12 AU AU2019303030A patent/AU2019303030B2/en active Active
- 2019-07-12 KR KR1020217003612A patent/KR20210030957A/ko active Pending
- 2019-07-12 CN CN201980060142.8A patent/CN112703205B/zh active Active
- 2019-07-12 EP EP19748736.6A patent/EP3820908A1/en active Pending
- 2019-07-12 US US17/259,677 patent/US12325742B2/en active Active
- 2019-07-12 MX MX2021000392A patent/MX2021000392A/es unknown
- 2019-07-12 JP JP2021500837A patent/JP7431211B2/ja active Active
-
2021
- 2021-01-07 IL IL280003A patent/IL280003A/en unknown
- 2021-02-02 ZA ZA2021/00721A patent/ZA202100721B/en unknown
-
2024
- 2024-02-01 JP JP2024013969A patent/JP7671377B2/ja active Active
-
2025
- 2025-05-02 US US19/197,359 patent/US20250368730A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN112703205A (zh) | 2021-04-23 |
| BR112021000399A2 (pt) | 2021-04-06 |
| AU2019303030A1 (en) | 2021-02-25 |
| IL280003A (en) | 2021-03-01 |
| US20220267421A1 (en) | 2022-08-25 |
| JP2021524278A (ja) | 2021-09-13 |
| MX2021000392A (es) | 2021-05-27 |
| WO2020011970A1 (en) | 2020-01-16 |
| EP3820908A1 (en) | 2021-05-19 |
| JP7431211B2 (ja) | 2024-02-14 |
| GB201811415D0 (en) | 2018-08-29 |
| SG11202013164RA (en) | 2021-01-28 |
| TWI840386B (zh) | 2024-05-01 |
| CA3105995A1 (en) | 2020-01-16 |
| CN112703205B (zh) | 2024-10-18 |
| TW202019971A (zh) | 2020-06-01 |
| AU2019303030B2 (en) | 2025-08-14 |
| US12325742B2 (en) | 2025-06-10 |
| KR20210030957A (ko) | 2021-03-18 |
| JP2024059643A (ja) | 2024-05-01 |
| US20250368730A1 (en) | 2025-12-04 |
| JP7671377B2 (ja) | 2025-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202100721B (en) | Anti-mesothelin antibodies | |
| PH12020500671A1 (en) | Antibodies specific for gucy2c and uses thereof | |
| ZA202308021B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
| MX2021015888A (es) | Fusión de un anticuerpo que se une a cea y 4-1bbl. | |
| SA517381703B1 (ar) | C10orf54 - أجسام مضادة لـ واستخداماتها | |
| EA201591611A1 (ru) | Конъюгаты антитело-лекарственное средство | |
| EA201892294A1 (ru) | Антитела и композиции против tim-3 | |
| WO2018190719A3 (en) | Anti-sirp alpha antibodies | |
| EP4417263A3 (en) | Cd3 binding antibodies | |
| MX393609B (es) | Anticuerpos anti pd-1 y anti-lag3 para el tratamiento de cancer | |
| MX2018012757A (es) | Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos. | |
| EA201790334A1 (ru) | Конъюгаты анти-cdh6 антитела с лекарственным средством | |
| MX2018006333A (es) | Anticuerpos anti-receptor de muerte 5 (dr5) y metodos de uso de los mismos. | |
| EA201691824A1 (ru) | АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ | |
| WO2019234241A8 (en) | ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT | |
| NZ743124A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
| PH12020552006A1 (en) | Antibodies specific for cd3 and uses thereof | |
| MX2019015738A (es) | Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos. | |
| JOP20190187A1 (ar) | مترافقات عقار جسم مضاد لـ ccr7 | |
| SA523440622B1 (ar) | أجسام مضادة | |
| EA202191769A1 (ru) | Тубулизины и конъюгаты белок-тубулизин | |
| ZA202008095B (en) | Humanized antibodies against psma | |
| PH12020551968A1 (en) | Anti-sez6 antibody drug conjugates and methods of use | |
| PH12019500802A1 (en) | Antibodies that bind zika virus envelope protein and uses thereof | |
| MX2020008122A (es) | Anticuerpos anti-pd-1. |